[CBAY] CymaBay Therapeutics Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 39.37 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.79 Change: 0.01 (0.56%)
Ext. hours: Change: 0 (0%)

chart CBAY

Refresh chart

Strongest Trends Summary For CBAY

CBAY is in the long-term up 883% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: There is no Profile data available for CBAY.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding22.37 M EPS-1.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-4.74
P/E To EPS Growth P/S P/BV2.16 Price/Cash Per Share1.2
Price/Free Cash Flow ROA-69.63% ROE-132.38% ROI-114.8%
Current Ratio2.52 Quick Ratio Long Term Debt/Equity0.13 Debt Ratio0.75
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.32 M Cash From Investing Activities1.1 M Cash From Operating Activities-6.16 M Gross Profit
Net Profit-2.33 M Operating Profit-6.78 M Total Assets34.73 M Total Current Assets34.49 M
Total Current Liabilities13.66 M Total Debt4.19 M Total Liabilities16.46 M Total Revenue
Technical Data
High 52 week15.16 Low 52 week5.95 Last close13.03 Last change-4.4%
RSI57.47 Average true range0.49 Beta0.98 Volume47.44 K
Simple moving average 20 days5.53% Simple moving average 50 days3.34% Simple moving average 200 days9.52%
Performance Data
Performance Week4.66% Performance Month17.39% Performance Quart4.07% Performance Half-9.26%
Performance Year110.16% Performance Year-to-date41.63% Volatility daily2.36% Volatility weekly5.27%
Volatility monthly10.8% Volatility yearly37.41% Relative Volume216.06% Average Volume777.64 K
New High New Low

News

2019-06-14 16:25:03 | CymaBay Therapeutics: What Investors Should Watch For

2019-06-14 14:55:03 | What’s Been Dragging Down CymaBay Therapeutics Stock

2019-06-14 13:21:25 | Intercept Pharmaceuticals, CymaBay’s and Viking’s Competitor

2019-06-14 13:21:24 | What Analysts Recommend for CBAY and VKTX

2019-06-12 18:27:10 | CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

2019-06-12 09:27:01 | Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

2019-06-12 08:53:00 | CymaBay Therapeutics Stock Plunged. Here’s Why It Could Be Time to Buy

2019-06-12 07:34:25 | The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

2019-06-11 16:15:04 | CymaBay Therapeutics Stock Crashes Over 50%: Is It Viable?

2019-06-11 12:25:00 | Here's Why CymaBay Therapeutics Collapsed Today

2019-06-11 09:02:43 | How Much Are CymaBay Therapeutics, Inc. NASDAQ:CBAY Insiders Spending On Buying Shares?

2019-06-11 08:58:00 | CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors

2019-06-11 08:30:30 | CymaBay Therapeutics Plummets 40% Following Liver Disease Data

2019-06-11 07:00:00 | CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

2019-06-10 14:50:53 | Steven Cohen Takes an Interest in CymaBay Therapeutics

2019-05-22 10:26:02 | Options Traders Expect Huge Moves in CymaBay Therapeutics CBAY Stock

2019-05-20 16:01:00 | CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019

2019-05-18 09:50:27 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

2019-05-09 20:31:30 | Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc CBAY

2019-05-09 06:19:32 | Edited Transcript of CBAY earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-08 16:05:00 | CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-08 08:00:00 | CymaBay Therapeutics Announces Multiple Presentations at DDW 2019

2019-05-02 15:43:41 | Genfit, Cymbay Hope to Crack Large Liver Disease Market

2019-04-30 08:00:00 | CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8

2019-04-12 09:04:45 | If You Had Bought CymaBay Therapeutics NASDAQ:CBAY Stock Three Years Ago, You Could Pocket A 703% Gain Today

2019-04-12 08:00:00 | CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019

2019-03-27 08:00:00 | CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019

2019-03-25 07:00:00 | Market Trends Toward New Normal in Louisiana-Pacific, The Michaels Companies, VEREIT, CymaBay Therapeutics, CareDx, and Harsco — Emerging Consolidated Expectations, Analyst Ratings

2019-03-12 08:00:00 | CymaBay Therapeutics to Present at Upcoming Investor Conferences in March

2019-03-11 16:05:00 | CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

2019-03-06 08:00:00 | CymaBay Announces Pricing of Public Offering of Common Stock

2019-03-05 16:01:00 | CymaBay Announces Proposed Public Offering of Common Stock

2019-03-01 06:59:49 | Edited Transcript of CBAY earnings conference call or presentation 28-Feb-19 9:30pm GMT

2019-02-28 23:24:56 | CymaBay Therapeutics Inc CBAY Q4 2018 Earnings Conference Call Transcript

2019-02-28 16:05:00 | CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update

2019-02-22 07:40:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries — New Research Emphasizes Economic Growth

2019-02-21 08:00:00 | CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28

2019-02-20 08:00:00 | CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-19 08:00:00 | CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

2019-02-15 08:00:00 | CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis

2019-02-07 09:20:58 | CymaBay Therapeutics, Inc. NASDAQ:CBAY: What Does Its Beta Value Mean For Your Portfolio?

2019-01-02 08:00:00 | CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-21 09:29:22 | Have Insiders Been Buying CymaBay Therapeutics, Inc. NASDAQ:CBAY Shares?

2018-12-12 00:10:39 | Hedge Funds Are Buying CymaBay Therapeutics Inc CBAY

2018-11-27 08:25:00 | Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and Upcoming Developments

2018-11-20 08:00:00 | CymaBay Therapeutics to Participate in Upcoming Investor Conferences

2018-11-13 08:00:00 | CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018

2018-11-06 21:14:55 | Edited Transcript of CBAY earnings conference call or presentation 6-Nov-18 9:30pm GMT

2018-11-06 16:10:00 | CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update

2018-10-30 16:05:00 | CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6